<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since receiving US regulatory approval in 2006 for the treatment of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, <z:chebi fb="0" ids="50131">decitabine</z:chebi> has also gained marketing approval in several other countries </plain></SENT>
<SENT sid="1" pm="."><plain>Rates of complete remission (CR) reported for <z:chebi fb="0" ids="50131">decitabine</z:chebi> range from 9% in the US registration trial to 34% in a study of novel treatment schedules, while reported overall improvement rates range from 30% to 73% </plain></SENT>
<SENT sid="2" pm="."><plain>Further studies are needed to determine the relative merits of <z:chebi fb="0" ids="50131">decitabine</z:chebi> compared with <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, the optimal <z:chebi fb="0" ids="50131">decitabine</z:chebi> dose and schedule, how best to proceed following CR, molecular predictors of treatment response, and the possible role of this agent in combination regimens </plain></SENT>
</text></document>